ITC's Colorectal Cancer Vaccine Enters Phase II
Patient enrollment in a Phase II trial of ImmunoTherapy Corp's vaccinefor the treatment of colorectal cancer, CTP37, is now complete. Clinical development of the vaccine is being undertaken by Arkios BioDevelopment International of Cincinnati, USA.
Phase I studies with CTP37 suggest that a range of metastatic tumors may respond to the vaccine, which induces antibodies against human chorionic gonadotrophin. hCG is generally expressed by neoplastic cells, and is thought to play a role in masking the tumors from the host immune response.
ITC and Arkios are also conducting Phase II trials in patients with advanced pancreatic cancer, and trials in breast and prostate cancer patients are scheduled to begin in 1997. In addition, a formulation of the vaccine that targets multiple sites on the hCG molecule is being developed in an attempt to improve the vaccine's effectiveness.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze